tag:blogger.com,1999:blog-7857054149675424609.post3519728242948654527..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Tectonic Shifts in RNAi TherapeuticsDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger14125tag:blogger.com,1999:blog-7857054149675424609.post-9985071954683312342011-05-11T03:17:50.778+00:002011-05-11T03:17:50.778+00:00Benitecs beefed up scientific advisory board just ...Benitecs beefed up scientific advisory board just had its first meeting -apparently a big boost in the area you highlighted is underway - delivery AAV , aptamers etc . The new management, board and recapitalization of this pioneer company not to mention the recent granting of core European patents ( which the media seems to have missed) indicate this company has been reinvigorated and is rapidly Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-85779385238455255422011-05-10T13:15:12.759+00:002011-05-10T13:15:12.759+00:00Yes, it will be interesting to see AMT's progr...Yes, it will be interesting to see AMT's progress in ddRNAi. I had read their recent paper on the knockdown of ApoB in mice. There is certainly room for technical improvement at AMT on the RNAi design side. <br /><br />That's also where I believe Benitec is (still) missing the opportunity to build more in-house ddRNAi expertise. In addition to a license, they ought to be a preferred Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-40009350612957897262011-05-10T12:52:25.473+00:002011-05-10T12:52:25.473+00:00try again:
http://www.streetinsider.com/Press+Rel...try again:<br /><br />http://www.streetinsider.com/Press+Releases/Amsterdam+Molecular+Therapeutics+Provides+Status+Update+on+Glybera(R)/6487517.htmlAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-34006802547808325912011-05-10T12:48:01.159+00:002011-05-10T12:48:01.159+00:00AMT's apparent progress seems to concur with y...AMT's apparent progress seems to concur with your thoughts Gene Genie.<br /><br />http://www.genengnews.com/keywordsandtools/print/2/117419687/Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-71890164471940185612011-05-10T00:46:43.100+00:002011-05-10T00:46:43.100+00:00I dont know why it is clear shRNA will never succe...I dont know why it is clear shRNA will never succeed ? Nature has developed 3 ways to deal with disease , medical science has discovered and developed these in reverse order . Small molecules almost all are derived from plant chemicals eg Aspirin , taxol , these chremicals or hard wired immunity is the reason rice has twice as many genes as humans. Next came antibodies , an adaptive immunity , isGene Genienoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-13168964869741073922011-05-08T18:27:19.850+00:002011-05-08T18:27:19.850+00:00Jerry- I don't mean to discourage the company ...Jerry- I don't mean to discourage the company or investors and curtailing R&D may not have been a choice taken lightly. But from my perspective, with no active R&D and an ageing pipeline asset stalled in the clinic, how do you think the company can ever expect to license out the technology?Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-79040560941911413042011-05-08T11:32:51.161+00:002011-05-08T11:32:51.161+00:00Re: Arrowhead.
Dirk, I am surprised at how glibly ...Re: Arrowhead.<br />Dirk, I am surprised at how glibly you dismiss ARWR:<br />"Arrowhead Research (ARWR), despite its name, has long stopped internal RNAi research and its technology is getting stale by the day,...."<br /><br />Could you elaborate? I may have been naive, but I liked the recent streamlining of the congolmerate and focus upon nanomedicine. Do you feel as negative about Jerryhttps://www.blogger.com/profile/01068055404938347482noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-35902850199082588192011-04-28T07:20:17.051+00:002011-04-28T07:20:17.051+00:00On ddRNAi: It's not quite so clear to me. If ...On ddRNAi: It's not quite so clear to me. If you followed the gene therapy space, there have been quite a few notable clinical successes recently (ocular, bone marrow, and metabolic disorders, and more in CNS to come) and the pharmaceutical industry (Sanofi, Pfizer, GSK etc) is clearly getting interested. <br /><br />On RNAi Rx as an accepted pharmacologic agent: Instead of fear-mongering,Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-76714982574459280862011-04-27T23:04:52.068+00:002011-04-27T23:04:52.068+00:00It's clear that these DNA directed shRNA produ...It's clear that these DNA directed shRNA production methods are not going to succeed. This is just another form of gene therapy, and it's wishful thinking. Similarly, counting on bacteria to deliver RNA is equally foolish.<br /><br />Big pharma will avoid these like the plague, and they stand a minimal chance of approval, and if approved, will be minor players in any therapeutic Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-31062737370308874762011-04-27T16:49:27.639+00:002011-04-27T16:49:27.639+00:00To add to that, there must be some deep pockets so...To add to that, there must be some deep pockets somewhere if you raise $10M. What is clear though is that the retail shareholder has lost once again.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-89680343903545956252011-04-27T16:47:12.251+00:002011-04-27T16:47:12.251+00:00I was wrong on Silence. Assuming the Company prot...I was wrong on Silence. Assuming the Company protects shareholder interest as they should, there are few ways to explain the timing other than that the ASCO results will be quite bad.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-36953281513811105822011-04-27T16:39:48.667+00:002011-04-27T16:39:48.667+00:00Pardon my ignorance, but what's the deal with...Pardon my ignorance, but what's the deal with silence therap. (SLN)?<br /><br />Why are they trading so low (sub 20mm) considering the deep financial backers?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-2417859392975248502011-04-26T09:18:44.158+00:002011-04-26T09:18:44.158+00:00Personally, I would not count on Pfizer for contin...Personally, I would not count on Pfizer for continued R&D support as they are quite busy shrinking. Even if Pfizer continued to support the Tacere program, it would be more an endorsement of Benitec's technology and have less an impact on Benitec's financial situation. <br /><br />PS: To clarify, after the re-capitalization, Benitec's market cap should be closer to $AUS24M?Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-16791867608867850042011-04-26T03:39:10.495+00:002011-04-26T03:39:10.495+00:00Thanks for your informative blog Dirk of which I a...Thanks for your informative blog Dirk of which I am a regular reader. I am a shareholder in Benitec. Their recent fully underwritten renounceable rights issue will see them with $AUS8million, enough for 2-3years and money to progress 3 key programs to the clinic, one of which is projected to enter human clinical trials within 2 years. I know things are bad for all companys involved with RNAi at Mr Squigglenoreply@blogger.com